Novel Anticoagulant Mechanisms
新型抗凝机制
基本信息
- 批准号:6682157
- 负责人:
- 金额:$ 37.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-29 至 2007-08-31
- 项目状态:已结题
- 来源:
- 关键词:SDS polyacrylamide gel electrophoresis anticoagulants blood proteins clinical research coagulation factor IX coagulation factor X genetic polymorphism human tissue laboratory mouse laboratory rabbit protease inhibitor protein protein interaction protein purification protein structure function prothrombin serine proteinases surface plasmon resonance western blottings
项目摘要
DESCRIPTION (provided by applicant): The long-term goal is to increase knowledge of mechanisms that regulate blood coagulation so that new antithrombotic therapies and preventative measures can be developed. Defects in coagulation regulation lead to increased risk of vascular disease, a major cause of death. Studies will focus on a novel coagulation regulator, protein Z-dependent protease inhibitor (ZPI) that rapidly inactivates Factor Xa (FXa) in the presence of protein Z, Ca 2+ and phospholipids (PL). Our studies show that ZPI/protein Z also inhibits FIXa. Low protein Z levels are associated with stroke, suggesting physiologic relevance. We hypothesize that: A) ZPI and protein Z are significant down-regulators of both FXa and FIXa; B) Mechanisms of ZPI inhibition differ from those of most serpins; D) ZPI inhibits FIXa and FXa by different mechanisms; and C) Defining ZPI mechanisms and sites of protein-protein interaction may lead to new antithrombotic therapies. Specific aims are: 1) Assess whether ZPI and protein Z are significant inhibitors of FXa and FIXa. We will determine if inhibition of both FXa and FIXa occurs at plasma levels of ZPI/protein Z, prothrombin and FX. We will assess the importance of ZPI inhibition of FXa vs. FlXa and determine if combined inhibitory effects are additive. We will find if FXa-ZPI or FlXa-ZPI are major complexes formed when FIXa or FXa are added to plasma. 2) Define mechanisms for ZPI/protein Z inhibition of FXa. Most serpins do not require a protein cofactor, PL or Ca 2+, and serpin-protease complexes are usually covalent and irreversible. Inhibition of FXa by ZPI seems to differ in these respects. We will elucidate ZPI's unusual mechanisms. We will find if cleavage of ZPI by FXa occurs and if ternary complexes of ZPI-protein Z-FXa can form. 3) Determine how mechanisms of ZPI inhibition of FIXa and FXa differ. FXa inhibition by ZPI strictly requires protein Z and FXa is partly protected from ZPI by FVa. We will extend findings suggesting that ZPI inhibition of FIXa does not require protein Z and that FVIIla enhances ZPI inhibition of FIXa. We will find the reasons for the differences and discover if ZPI inhibition of FIXa differs from that of FXa with respect to binary/ternary complexes, covalency of complexes, or reversibility. 4) Elucidate structure-function relationships for ZPI and protein Z that lead to FIXa or FXa inhibition. We will define some of the regions crucial for interaction between these proteins by performing functional studies with modified proteins, selected mutants of rZPI and peptides representing candidate sequences for interactions. We will find whether a ZPI polymorphism we identified affects function.
描述(由申请人提供):长期目标是增加对调节凝血机制的了解,以便开发新的抗血栓疗法和预防措施。凝血调节的缺陷会增加血管疾病的风险,而血管疾病是导致死亡的主要原因。研究将集中在一种新型的凝血调节剂,即蛋白Z依赖的蛋白酶抑制物(ZPI),它能在蛋白Z、钙和磷脂(PL)存在的情况下快速灭活Xa因子(FXA)。我们的研究表明,ZPI/Protein Z也抑制FixA。低蛋白Z水平与中风有关,提示与生理相关。我们假设:A)ZPI和蛋白Z对FXA和FIXA都有显著的下调作用;B)ZPI的抑制机制不同于大多数蛇;D)ZPI通过不同的机制抑制FXA和FXA;以及C)确定ZPI的机制和蛋白质相互作用的位置可能导致新的抗血栓治疗。具体目标是:1)评估ZPI和蛋白Z是否是FXA和FixA的显著抑制剂。我们将在血浆ZPI/蛋白Z、凝血酶原和FX水平上确定是否同时抑制FXA和FIXA。我们将评估FXA和FlXa的ZPI抑制的重要性,并确定联合抑制效应是否是相加的。我们将发现FXA-ZPI或FlXa-ZPI是当FIXA或FXA加入到血浆中时形成的主要络合物。2)明确ZPI/Protein Z抑制FXA的机制。大多数蛇类不需要蛋白质辅因子PL或Ca~(2+),而且蛇胶-蛋白酶复合体通常是共价的和不可逆的。ZPI对FXA的抑制似乎在这些方面有所不同。我们将阐明ZPI的不寻常机制。我们将发现ZPI是否被FXA切割,以及是否能形成ZPI-蛋白质Z-FXA的三元复合体。3)确定FIXA和FXA抑制ZPI的机制有何不同。ZPI对FXA的抑制严格要求蛋白Z,FVA对FXA有部分保护作用。我们将扩大研究结果,表明抑制ZPI的FixA不需要蛋白质Z,而FVIIla增强了FixA的ZPI抑制。我们将找出差异的原因,并发现FixA和FXA的ZPI抑制是否在二元/三元络合物、络合物的共价性或可逆性方面不同。4)阐明ZPI和蛋白Z的结构-功能关系导致FIXA或FXA抑制。我们将通过对修饰的蛋白质、rZPI的选定突变体和代表候选相互作用序列的多肽进行功能研究,来定义这些蛋白质之间相互作用的一些关键区域。我们将发现我们发现的ZPI多态是否会影响功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARY J HEEB其他文献
MARY J HEEB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARY J HEEB', 18)}}的其他基金
New Aspects of Protein S Anticoagulant Activity
Protein S 抗凝活性的新方面
- 批准号:
7524692 - 财政年份:2008
- 资助金额:
$ 37.54万 - 项目类别:
New Aspects of Protein S Anticoagulant Activity
Protein S 抗凝活性的新方面
- 批准号:
7895735 - 财政年份:2008
- 资助金额:
$ 37.54万 - 项目类别:
New Aspects of Protein S Anticoagulant Activity
Protein S 抗凝活性的新方面
- 批准号:
7664967 - 财政年份:2008
- 资助金额:
$ 37.54万 - 项目类别:
FORMS OF PROSTATE SPECIFIC ANTIGEN AND HK2 IN CANCER
癌症中前列腺特异性抗原和 HK2 的形式
- 批准号:
6150143 - 财政年份:1993
- 资助金额:
$ 37.54万 - 项目类别:
DIFFERENT FORMS OF PROSTATE-SPECIFIC ANTIGEN IN CANCER
癌症中不同形式的前列腺特异性抗原
- 批准号:
2100587 - 财政年份:1993
- 资助金额:
$ 37.54万 - 项目类别:
DIFFERENT FORMS OF PROSTATE-SPECIFIC ANTIGEN IN CANCER
癌症中不同形式的前列腺特异性抗原
- 批准号:
3460768 - 财政年份:1993
- 资助金额:
$ 37.54万 - 项目类别:
DIFFERENT FORMS OF PROSTATE-SPECIFIC ANTIGEN IN CANCER
癌症中不同形式的前列腺特异性抗原
- 批准号:
2100588 - 财政年份:1993
- 资助金额:
$ 37.54万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 37.54万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 37.54万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 37.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 37.54万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 37.54万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 37.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 37.54万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 37.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 37.54万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 37.54万 - 项目类别:
Studentship Programs